adalimumab,Etanercept
Abbvie,Amgen
[]
pappas et al. corevitas study. switch to etn or jaki as 2nd line following 1st line failure ada. survival 6 months 60% vs 77%, 12 months 47% vs 67%. jaki switch better but many patients do fine with 2nd tnfi. #acr22 abstr#1588 
Rheumatologist @stjamesdublin , Associate Professor @tcddublin , Acute Medicine, Vasculitis, ILD, Retired @Emeunet Executive Committee member, @rheum_covid CASC